

## Relatório de Dados da Disciplina

Sigla: RGO5853 - 2 Tipo: POS

Nome: Etiopatogenia da Síndrome dos Ovários Policísticos: Avaliação Multifatorial do Estágio Fetal à Menopausa

Área: Ginecologia e Obstetrícia (17145)

Datas de aprovação:

CCP: 18/05/2016 CPG: 07/06/2016 CoPGr:

Data de ativação: 07/06/2016 Data de desativação:

Carga horária:

Total: 60 h Teórica: 4 h Prática: 7 h Estudo: 9 h

Créditos: 4 Duração: 3 Semanas

1960042 - Rosana Maria dos Reis - 07/06/2016 até data atual  
Responsáveis: 6076969 - Lucia Alves da Silva Lara - 07/06/2016 até data atual  
6422669 - Anderson Sanches de Melo - 07/06/2016 até data atual

Objetivos:

Fornecer visão integrativa da etiopatogenia, fisiopatologia e aspectos clínicos, reprodutivos e laboratoriais relacionados à síndrome dos ovários policísticos (SOP) em todas as fases da vida da mulher.

Justificativa:

Apesar de ter sido descrita em 1935, vários aspectos fisiopatológicos da SOP ainda não foram elucidados. Segundo o último consenso das Sociedades Americana (ASRM) e Européia (ESHRE) de 2012, a maioria absoluta das evidências científicas relacionadas a este distúrbio encontra-se com grau de evidência B. No Brasil, a prevalência de SOP é 13,9% e as portadoras deste distúrbio podem antecipar manifestações clínicas e metabólicas para estágios precoces da vida, sendo que estas alterações podem estar relacionadas com o desenvolvimento de alterações reprodutivas e de doenças cardiovasculares (DCV). Como a DCV é a principal causa de morbimortalidade no Brasil, o estudo da fisiopatologia da SOP poderá contribuir para implementação de medidas adequadas de prevenção, diagnóstico precoce e tratamento. Desta forma, a proposta desta disciplina é integrar conhecimentos básicos da fisiopatologia e etiopatogenia da SOP e com o desenvolvimento de manifestações reprodutivas, metabólicas, sexuais e cardiovascular em diferentes fases da vida da mulher.

Conteúdo:

**AULAS TEÓRICAS:**

Teórica 1: Desenvolvimento ovariano durante a embriogênese, período fetal, infância e puberdade.

Teórica 2: Etiopatogenia multifatorial da SOP

Teórica 3: Ovários Policísticos-Bases Teóricas dos Modelos Experimentais (Valerato de estradiol e estresse).

Teórica 4: Aspectos metabólicos relacionados à SOP.

Teórico 5: Aspectos reprodutivos relacionados à SOP

**SEMINÁRIOS**

Seminário 1: Riscos da SOP para a qualidade de vida (cardiovascular, câncer, função sexual, diabetes tipo II, outros).

Seminário 2: Implicações perinatais sobre sua prole de mulheres com SOP

Seminário 3: Sexualidade em mulheres com SOP

Seminário 4: Modificações nos hábitos de vida de mulheres com SOP

Seminário 5: Foliculogênese na SOP

Seminário 6: Aspectos genéticos relacionados à SOP.

**AULAS PRÁTICAS:**

Prática 1: Histologia do ovário neonatal e puberal.

Prática 2: Correlação de aspectos macroscópicos e microscópicos de ovários de mulheres normais e com SOP.

## Relatório de Dados da Disciplina

Prática 3: Modelo experimental de ovários policísticos: Aspectos microscópicos do ovário policístico induzido por estresse em ratas.

### Bibliografia:

1. (2012). Consensus on women's health aspects of polycystic ovary syndrome (PCOS). *Hum Reprod* 27(1): 14-24.
2. Akbarzadeh, S., S. Ghasemi, et al. (2012). "Relationship among plasma adipokines, insulin and androgens level as well as biochemical glycemc and lipidemic markers with incidence of PCOS in women with normal BMI." *Gynecol Endocrinol*.
3. Barria, A., V. Leyton, et al. (1993). "Ovarian steroidal response to gonadotropins and beta-adrenergic stimulation is enhanced in polycystic ovary syndrome: role of sympathetic innervation." *Endocrinology* 133(6): 2696-2703.
4. Benitez, R., T. Sir-Petermann, et al. (2001). "[Prevalence of metabolic disorders among family members of patients with polycystic ovary syndrome]." *Rev Med Chil* 129(7): 707-712.
5. Bernuci, M. P., R. E. Szawka, et al. (2008). "Locus coeruleus mediates cold stress-induced polycystic ovary in rats." *Endocrinology* 149(6): 2907-2916.
6. Brown, Z. A., Y. V. Louwers, et al. (2011). "The phenotype of polycystic ovary syndrome ameliorates with aging." *Fertil Steril* 96(5): 1259-1265.
7. D'Albora, H., G. Anesetti, et al. (2002). "Intrinsic neurons in the mammalian ovary." *Microsc Res Tech* 59(6): 484-489.
8. de Paula Martins, W., L. F. Santana, et al. (2007). "Agreement among insulin sensitivity indexes on the diagnosis of insulin resistance in polycystic ovary syndrome and ovulatory women." *Eur J Obstet Gynecol Reprod Biol* 133(2): 203-207.
9. de Resende, L. O., R. M. dos Reis, et al. (2010). "[Concentration of steroid hormones in the follicular fluid of mature and immature ovarian follicles of patients with polycystic ovary syndrome submitted to in vitro fertilization]." *Rev Bras Ginecol Obstet* 32(9): 447-453.
10. Demir, B., S. Pasa, et al. (2011). "Morphologic and functional vascular alterations in patients with polycystic ovary syndrome." *Clin Exp Obstet Gynecol* 38(4): 401-404.
11. Dissen, G. A., C. Garcia-Rudaz, et al. (2009). "Excessive ovarian production of nerve growth factor facilitates development of cystic ovarian morphology in mice and is a feature of polycystic ovarian syndrome in humans." *Endocrinology* 150(6): 2906-2914.
12. Dissen, G. A., C. Garcia-Rudaz, et al. (2006). "Expression of the insulin receptor-related receptor is induced by the preovulatory surge of luteinizing hormone in thecal-interstitial cells of the rat ovary." *Endocrinology* 147(1): 155-165.
13. Dissen, G. A., D. F. Hill, et al. (1996). "A role for trkA nerve growth factor receptors in mammalian ovulation." *Endocrinology* 137(1): 198-209.
14. Dissen, G. A., H. E. Lara, et al. (1994). "Immature rat ovaries become revascularized rapidly after autotransplantation and show a gonadotropin-dependent increase in angiogenic factor gene expression." *Endocrinology* 134(3): 1146-1154.
15. Dissen, G. A., H. E. Lara, et al. (2000). "Intraovarian excess of nerve growth factor increases androgen secretion and disrupts estrous cyclicity in the rat." *Endocrinology* 141(3): 1073-1082.
16. Dissen, G. A., C. Romero, et al. (2002). "Neurotrophic control of ovarian development." *Microsc Res Tech* 59(6): 509-515.
17. Dorfman, M., V. D. Ramirez, et al. (2009). "Chronic-intermittent cold stress in rats induces selective ovarian insulin resistance." *Biol Reprod* 80(2): 264-271.
18. dos Reis, R. M., M. C. Foss, et al. (1995). "Insulin secretion in obese and non-obese women with polycystic ovary syndrome and its relationship with hyperandrogenism." *Gynecol Endocrinol* 9(1): 45-50.
19. Fauser, B. C., B. C. Tarlatzis, et al. (2012). "Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group." *Fertil Steril* 97(1): 28-38 e25.
20. Fernandes, A. R., A. C. de Sa Rosa e Silva, et al. (2005). "Insulin resistance in adolescents with menstrual irregularities." *J Pediatr Adolesc Gynecol* 18(4): 269-274.
21. Fernandes, J. B., G. M. Soares, et al. (2009). "[Obesity and altered arterial structure in young women with micropolycystic ovary syndrome]." *Rev Bras Ginecol Obstet* 31(7): 342-348.
22. Ferriani, R. A., M. F. Silva de Sa, et al. (1989). "Dopamine might not be involved in the pathogenesis of polycystic ovary syndrome." *Gynecol Endocrinol* 3(4): 317-327.
23. Ferruz, J., C. E. Ahmed, et al. (1992). "Norepinephrine release in the immature ovary is regulated by autoreceptors and neuropeptide-Y." *Endocrinology* 130(3): 1345-1351.
24. Fleischman, A. and J. Mansfield (2005). "Diagnosis and treatment of polycystic ovarian syndrome and insulin resistance." *Pediatr Ann* 34(9): 733-738, 741-732.
25. Franceschi, R., R. Gaudino, et al. (2010). "Prevalence of polycystic ovary syndrome in young women who had idiopathic central precocious puberty." *Fertil Steril* 93(4): 1185-1191.
26. Halperin, I. J., S. S. Kumar, et al. (2011). "The association between the combined oral contraceptive pill and insulin resistance, dysglycemia and dyslipidemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of observational studies." *Hum Reprod* 26(1): 191-201.
27. Kravariti, M., K. K. Naka, et al. (2005). "Predictors of endothelial dysfunction in young women with polycystic ovary syndrome." *J Clin Endocrinol Metab* 90(9): 5088-5095.
28. Lakhani, K., G. M. Prelevic, et al. (2004). "Polycystic ovary syndrome, diabetes and cardiovascular disease: risks and risk factors." *J Obstet Gynaecol* 24(6): 613-621.

## Relatório de Dados da Disciplina

29. Lane, D. E. (2006). "Polycystic ovary syndrome and its differential diagnosis." *Obstet Gynecol Surv* 61(2): 125-135.
30. Lara, H. E., W. L. Dees, et al. (1991). "Functional recovery of the developing rat ovary after transplantation: contribution of the extrinsic innervation." *Endocrinology* 129(4): 1849-1860.
31. Lara, H. E., G. A. Dissen, et al. (2000). "An increased intraovarian synthesis of nerve growth factor and its low affinity receptor is a principal component of steroid-induced polycystic ovary in the rat." *Endocrinology* 141(3): 1059-1072.
32. Lara, H. E., J. L. Ferruz, et al. (1993). "Activation of ovarian sympathetic nerves in polycystic ovary syndrome." *Endocrinology* 133(6): 2690-2695.
33. Lara, H. E., D. F. Hill, et al. (1990). "The gene encoding nerve growth factor is expressed in the immature rat ovary: effect of denervation and hormonal treatment." *Endocrinology* 126(1): 357-363.
34. Lara, H. E., J. K. McDonald, et al. (1990). "Guanethidine-mediated destruction of ovarian sympathetic nerves disrupts ovarian development and function in rats." *Endocrinology* 127(5): 2199-2209.
35. Lara, H. E., J. K. McDonald, et al. (1990). "Involvement of nerve growth factor in female sexual development." *Endocrinology* 126(1): 364-375.
36. Lass, N., M. Kleber, et al. (2011). "Effect of lifestyle intervention on features of polycystic ovarian syndrome, metabolic syndrome, and intima-media thickness in obese adolescent girls." *J Clin Endocrinol Metab* 96(11): 3533-3540.
37. Maliqueo, M., I. Atwater, et al. (2003). "Proinsulin serum concentrations in women with polycystic ovary syndrome: a marker of beta-cell dysfunction?" *Hum Reprod* 18(12): 2683-2688.
38. Maliqueo, M., M. Clementi, et al. (2003). "Expression of steroid receptors and proteins related to apoptosis in endometria of women with polycystic ovary syndrome." *Fertil Steril* 80 Suppl 2: 812-819.
39. Martins, W. P., C. O. Nastri, et al. (2009). "Flow-mediated dilatation in polycystic ovary syndrome women." *Fertil Steril* 91(5): e23; author reply e24.
40. Mayerhofer, A., M. Danilchik, et al. (1996). "Testis of prepubertal rhesus monkeys receives a dual catecholaminergic input provided by the extrinsic innervation and an intragonadal source of catecholamines." *Biol Reprod* 55(3): 509-518.
41. Mayerhofer, A., G. D. Smith, et al. (1998). "Oocytes are a source of catecholamines in the primate ovary: evidence for a cell-cell regulatory loop." *Proc Natl Acad Sci U S A* 95(18): 10990-10995.
42. Melo, A. S., C. S. Vieira, et al. (2010). "High prevalence of polycystic ovary syndrome in women born small for gestational age." *Hum Reprod* 25(8): 2124-2131.
43. Meyer, C., B. P. McGrath, et al. (2005). "Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease." *J Clin Endocrinol Metab* 90(10): 5711-5716.
44. Norman, R. J., D. Dewailly, et al. (2007). "Polycystic ovary syndrome." *Lancet* 370(9588): 685-697.
45. Nybacka, A., K. Carlstrom, et al. (2011). "Randomized comparison of the influence of dietary management and/or physical exercise on ovarian function and metabolic parameters in overweight women with polycystic ovary syndrome." *Fertil Steril* 96(6): 1508-1513.
46. Orio, F., Jr., S. Palomba, et al. (2005). "Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study." *J Clin Endocrinol Metab* 90(11): 6072-6076.
47. Ortiz Nunez, D. A., I. Hernandez Marin, et al. (2005). "[Insulin sensitizers in the treatment of polycystic ovary]." *Ginecol Obstet Mex* 73(6): 315-327.
48. Palomba, S., A. Falbo, et al. (2011). "Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced ovarian reserve? A randomized controlled trial." *Fertil Steril* 96(5): 1128-1133.
49. Palomba, S., A. Falbo, et al. (2010). "Systemic and local effects of metformin administration in patients with polycystic ovary syndrome (PCOS): relationship to the ovulatory response." *Hum Reprod* 25(4): 1005-1013.
50. Perez-Bravo, F., B. Echiburru, et al. (2005). "Tryptophan 64 --> arginine polymorphism of beta-3-adrenergic receptor in Chilean women with polycystic ovary syndrome." *Clin Endocrinol (Oxf)* 62(2): 126-131.
51. Premoli, A. C., L. F. Santana, et al. (2005). "Growth hormone secretion and insulin-like growth factor-1 are related to hyperandrogenism in nonobese patients with polycystic ovary syndrome." *Fertil Steril* 83(6): 1852-1855.
52. Reaven, G. M. (2005). "Insulin resistance, the insulin resistance syndrome, and cardiovascular disease." *Panminerva Med* 47(4): 201-210.
53. Santana, L. F., M. F. de Sa, et al. (2004). "Effect of metformin on the clinical and metabolic assessment of women with polycystic ovary syndrome." *Gynecol Endocrinol* 19(2): 88-96.
54. Sir-Petermann, T. (2005). "Polycystic ovary syndrome, a pathway to type 2 diabetes." *Nutrition* 21(11-12): 1160-1163.
55. Sir-Petermann, T., F. Alba, et al. (1998). "[Polycystic ovary syndrome: relationship of insulin tissular sensitivity, LH secretion and ovarian morphophysiological changes]." *Rev Med Chil* 126(9): 1049-1057.
56. Sir-Petermann, T., B. Angel, et al. (2002). "Prevalence of Type II diabetes mellitus and insulin resistance in parents of women with polycystic ovary syndrome." *Diabetologia* 45(7): 959-964.
57. Sir-Petermann, T., C. Hitchensfeld, et al. (2005). "Birth weight in offspring of mothers with polycystic ovarian syndrome." *Hum Reprod* 20(8): 2122-2126.
58. Sir-Petermann, T., M. Maliqueo, et al. (2002). "Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization." *Hum Reprod* 17(10): 2573-2579.
59. Sir-Petermann, T., M. Maliqueo, et al. (2001). "[Polycystic ovary syndrome: the importance of establishing diagnosis]." *Rev Med Chil* 129(7): 805-812.
60. Smith, S. S. and S. R. Ojeda (1984). "Maternal modulation of infantile ovarian development and available ovarian luteinizing hormone-releasing hormone (LHRH) receptors via milk LHRH." *Endocrinology* 115(5): 1973-1983.
61. Soares, G. M., C. S. Vieira, et al. (2009). "Metabolic and cardiovascular impact of oral contraceptives in polycystic

## Relatório de Dados da Disciplina

---

ovary syndrome." Int J Clin Pract 63(1): 160-169.

62. Urbanski, H. F. and S. R. Ojeda (1985). "The juvenile-peripubertal transition period in the female rat: establishment of a diurnal pattern of pulsatile luteinizing hormone secretion." Endocrinology 117(2): 644-649.

63. Wood, J. R., D. A. Dumesic, et al. (2007). "Molecular abnormalities in oocytes from women with polycystic ovary syndrome revealed by microarray analysis." J Clin Endocrinol Metab 92(2): 705-713.

64. Zachurzok-Buczynska, A., L. Szydlowski, et al. (2011). "Blood pressure regulation and resting heart rate abnormalities in adolescent girls with polycystic ovary syndrome." Fertil Steril 96(6): 1519-1525.

65. Melo AS, Dias SV, Cavalli Rde C, Cardoso VC, Bettiol H, Barbieri MA, Ferriani RA, Vieira CS. Pathogenesis of polycystic ovary syndrome: multifactorial assessment from the foetal stage to menopause. Reproduction. 2015;150(1):R11-24.

66. Melo AS, Bettiol H, Silva AA, Rosa-e-Silva AC, Cardoso VC, Reis RM, Ferriani RA, Barbieri MA, Vieira CS. Small for gestational age babies are not related to changes in markers of adipose tissue dysfunction during reproductive age. Early Hum Dev. 2014;90(5):231-5.

Forma de avaliação:

1. Frequência
2. Interesse pelo curso
3. Apresentação de seminários

Observação:

PÚBLICO ALVO: pós-graduandos prioritariamente matriculados em programas relacionados à reprodução.